Oramed Pharma Shares Sink After Diabetes Candidate Fails In Phase 3 Study – Yahoo Finance

Oramed Pharmaceuticals Inc (NASDAQ: ORMP) announced top-line results from its Phase 3 trial (ORA-D-013-1) comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes (T2D) at 26 weeks.
ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents.
The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from baseline in A1C at 26 weeks.
The trial also did not meet its secondary endpoint, which assessed the mean change from baseline in fasting plasma glucose at 26 weeks.
There were no serious drug-related adverse events. Therefore, Oramed expects to discontinue its oral insulin clinical activities for T2D.
CEO Nadav Kidron commented, “Today’s outcome is very disappointing, given the positive results from prior trials. Once full data from the studies are available, we expect to share relevant learnings and future plans.”
In November, Oramed announced additional data from its Phase 2 trial (ORA-D-N02) of oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis (NASH).
The whole Liver showed a placebo-adjusted mean decrease in liver fat content of 0.96 with a placebo-adjusted median decrease of 6.0 for ORMD-0801.
Price Action: ORMP shares are down 68% at $3.45 during the premarket session on the last check Thursday.
Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Related Quotes
She said she "gained double the weight back" after stopping the medication.
The year 2023 brings changes to the rules, limits and options on all kinds of federal programs and Medicare is no exception. Roughly 65 million senior citizens who rely on Medicare for health coverage will pay less for several things, … Continue reading → The post 6 Medicare Changes in 2023, Including Free Shingles Vaccines and Negotiable Prescription Prices appeared first on SmartAsset Blog.
Pharmaceutical companies Bayer (OTC: BAYR.Y), Eli Lilly (NYSE: LLY), and AstraZeneca (NASDAQ: AZN) had big years last year, bucking the rest of the market, and each stock saw share gains over the past year. All three companies have new drugs that were either recently launched or are likely to get final regulatory approval in 2023. Bayer's stock is up more than 4.5% over the past year, thanks to strong financials and an even stronger pipeline.
The Food and Drug Administration expanded the label for Novo Nordisk's oral diabetes medicine, leading NVO stock to jump Friday.
Pharmaceutical companies are grappling with the arrival in the U.S. of sweeping new legislation meant to blunt drug prices. The impact in 2023 may actually be higher drug prices. President Biden last year signed into law the bill dubbed the Inflation Reduction Act, empowering Medicare, the country’s biggest buyer of prescription drugs, to negotiate how much it pays for certain high-price therapies.
10,000 may be an arbitrary number, but the daily step goal has helped improve my mental and physical health
San Francisco's harm reduction centers provide syringes, tinfoil and pipes for drug users and have not made the city's homeless crisis any better, activist says.
Novavax (NVAX) is readying its forces to be a fully commercially-licensed company by the end of 2023, with a strong balance sheet and the workforce to achieve the endpoint.
New York City health authorities warned that the highly transmissible omicron subvariant XBB.1.5 may be more likely to infect those who have been vaccinated against COVID-19.
Many Americans compromise their own long-term financial security to care for loved ones.
Grace Garcia was diagnosed with stage 1 cancer after a cut on her finger — which she got during a manicure — didn't heal normally
A former nurse practitioner for CVS claimed she had been discriminated against for her religious beliefs in a lawsuit filed against the company Wednesday after she had been fired for refusing to prescribe birth control.
Damar Hamlin visited with teammates at the Bills facility on Saturday for the first time since being discharged from a Buffalo hospital, and about two weeks after the safety went into cardiac arrest and needed to be resuscitated on the field during a game in Cincinnati.
Ozempic, a once-weekly injection used to treat diabetes, has recently become TikTok’s newest diet trend
Ikaria Lean Belly Juice is one of the most popular weight loss powders on the market, but do the ingredients work for customers without side effects or are there negative complaints to worry about?
The Centers for Disease Control and Prevention has identified a "safety signal" in the Bivalent Pfizer-BioNTech vaccine and is investigating whether the shot creates an increased stroke risk for people 65 and older.
The CDC announced Friday that it is investigating "safety concerns" linked to the use of the Pfizer Covid vaccine in seniors.
Check yourself regularly
A pancreatic Cancer UK specialist nurse outlines easy-to-ignore signs of the disease
The new variant is currently responsible for 40% of all COVID cases across the country.

source